Online inquiry

IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8701MR)

This product GTTS-WQ8701MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets F3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001178096.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2152
UniProt ID P13726
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8701MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9097MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMCgp100
GTTS-WQ2810MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG-301
GTTS-WQ6865MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DX-2930
GTTS-WQ6432MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CT-P22
GTTS-WQ3913MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BCD-135
GTTS-WQ5178MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CAT-354
GTTS-WQ4943MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ14697MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SCT-400
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW